Suppr超能文献

HPC2/ELAC2基因的Ser217Leu多态性与日本男性前列腺癌风险相关。

Ser217Leu polymorphism of the HPC2/ELAC2 gene associated with prostatic cancer risk in Japanese men.

作者信息

Takahashi Hiroyuki, Lu Wei, Watanabe Masatoshi, Katoh Takahiko, Furusato Masakuni, Tsukino Hiromasa, Nakao Hiroyuki, Sudo Akemi, Suzuki Hiroyoshi, Akakura Koichiro, Ikemoto Isao, Asano Kouji, Ito Takaaki, Wakui Shin, Muto Tomoko, Hano Hiroshi

机构信息

Department of Pathology, Jikei University School of Medicine, Tokyo, Japan.

出版信息

Int J Cancer. 2003 Nov 1;107(2):224-8. doi: 10.1002/ijc.11347.

Abstract

The HPC2/ELAC2 gene may be associated with hereditary/familial prostate cancer (PCa). Two common missense variants (Ser217Leu and Ala541Thr) have been reported in the gene. We performed mutational, allelotyping and expression analyses and a molecular epidemiological study to clarify the relations between this gene and prostatic diseases, including PCa and benign prostatic hyperplasia (BPH) in Japanese men. We screened for mutations in 109 patients with PCa including 11 patients from 1 hereditary and 9 familial PCa. Loss of heterozygosity and expression were analyzed. An epidemiological study was done in sporadic PCa (n=98) and BPH (n=143) using 1 novel (Ser627Leu) and 2 previously described polymorphisms of the HPC2/ELAC2 gene. Somatic or germline mutations were not confirmed in any cases of PCa. Loss of heterozygosity at 2 microsatellites, D17S1289 and D17S520, was detected in 1 of 38 and 1 of 35 cases, respectively. Expression analysis revealed decreased or absent mRNA expression in 6 of 38 tumors. Epidemiologic analysis showed that a Leu allele at codon 217 was significantly more frequent in patients with PCa than in controls (10.2% vs. 3.5%, odds ratio = 3.11; 95% confidence interval, 1.22-7.90). At codon 541, all patients with PCa or BPH and all control subjects had the Ala/Ala genotype. At codon 627, the incidence of the Leu variant was slightly, but not significantly, higher in patients with BPH than in controls (7.0% vs. 2.8%, odds ratio = 2.59, 95% confidence interval, 0.94-7.13, not statistically significant). We concluded that germline/somatic mutations of HPC2/ELAC2 are uncommon in PCa. Similarly, allelic imbalances at the gene locus and changes in expression are rare. Although no difference in allele frequency at Ser217Leu between patients with PCa and controls has been reported in a Western population, this polymorphism is a potential indicator of PCa risk in Japanese men and it should be examined in other ethnic groups.

摘要

HPC2/ELAC2基因可能与遗传性/家族性前列腺癌(PCa)相关。该基因已报道有两种常见的错义变异(Ser217Leu和Ala541Thr)。我们进行了突变、等位基因分型和表达分析以及一项分子流行病学研究,以阐明该基因与前列腺疾病之间的关系,这些疾病包括日本男性中的前列腺癌和良性前列腺增生(BPH)。我们在109例前列腺癌患者中筛查了突变,其中包括11例来自1个遗传性和9个家族性前列腺癌的患者。分析了杂合性缺失和表达情况。使用1个新的(Ser627Leu)和2个先前描述的HPC2/ELAC2基因多态性,对散发性前列腺癌(n = 98)和良性前列腺增生(n = 143)进行了一项流行病学研究。在任何前列腺癌病例中均未证实存在体细胞或种系突变。在38例中的1例和35例中的1例中,分别检测到2个微卫星D17S1289和D17S520处的杂合性缺失。表达分析显示,38个肿瘤中有6个的mRNA表达降低或缺失。流行病学分析表明,密码子217处的Leu等位基因在前列腺癌患者中比在对照组中显著更常见(10.2%对3.5%,优势比 = 3.11;95%置信区间,1.22 - 7.90)。在密码子541处,所有前列腺癌或良性前列腺增生患者以及所有对照受试者均具有Ala/Ala基因型。在密码子627处,良性前列腺增生患者中Leu变异的发生率略高于对照组,但无显著差异(7.0%对2.8%,优势比 = 2.59,95%置信区间,0.94 - 7.13,无统计学意义)。我们得出结论,HPC2/ELAC2的种系/体细胞突变在前列腺癌中并不常见。同样,基因座处的等位基因失衡和表达变化也很少见。尽管在西方人群中尚未报道前列腺癌患者和对照组在Ser217Leu处的等位基因频率存在差异,但这种多态性是日本男性前列腺癌风险的一个潜在指标,应在其他种族群体中进行研究。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验